一项研究瑞米布替尼与安慰剂对成人全身性重症肌无力患者的疗效、安全性和耐受性的研究 (RELIEVE)
一项随机、双盲、安慰剂对照 III 期研究,旨在评估瑞布替尼治疗全身性重症肌无力患者的疗效、安全性和耐受性,随后进行开放标签扩展阶段
A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
研究概览
详细说明
This study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate the efficacy, safety and tolerability of remibrutinib in gMG patients who are on stable SOC treatment. Approximately 180 eligible participants will be randomized in a ratio of 1:1, to receive either remibrutinib or matching placebo.
The study consists of a Core Part (6-months double-blind treatment) and an Extension Part (up to 60-month open-label treatment).
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Beijing、中国、100730
- Novartis Investigative Site
-
Beijing、中国、100034
- Novartis Investigative Site
-
Qingdao、中国、266000
- Novartis Investigative Site
-
Shanghai、中国、200080
- Novartis Investigative Site
-
Shanghai、中国、200040
- Novartis Investigative Site
-
-
Anhui
-
Hefei、Anhui、中国、230001
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510080
- Novartis Investigative Site
-
-
Hebei
-
Shijiazhuang、Hebei、中国、050030
- Novartis Investigative Site
-
-
Henan
-
Zhengzhou、Henan、中国、450003
- Novartis Investigative Site
-
-
Hubei
-
Wuhan、Hubei、中国、430030
- Novartis Investigative Site
-
-
Jiangsu
-
Wuxi、Jiangsu、中国、214023
- Novartis Investigative Site
-
-
Jilin
-
Changchun、Jilin、中国、130021
- Novartis Investigative Site
-
-
-
-
-
Kutaisi、乔治亚州、4600
- Novartis Investigative Site
-
Tbilisi、乔治亚州、0114
- Novartis Investigative Site
-
Tbilisi、乔治亚州、0144
- Novartis Investigative Site
-
-
-
-
Ontario
-
London、Ontario、加拿大、N6A 5W9
- Novartis Investigative Site
-
Ottawa、Ontario、加拿大、K1H 8L6
- Novartis Investigative Site
-
-
Quebec
-
Québec、Quebec、加拿大、G1J 1Z4
- Novartis Investigative Site
-
-
-
-
Haryana
-
Gurugram、Haryana、印度、122011
- Novartis Investigative Site
-
-
Karnataka
-
Mangalore、Karnataka、印度、575002
- Novartis Investigative Site
-
-
Maharashtra
-
Nashik、Maharashtra、印度、422005
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi、National Capital Territory of Delhi、印度、110029
- Novartis Investigative Site
-
-
Punjab
-
Ludhiana、Punjab、印度、141001
- Novartis Investigative Site
-
-
Tamil Nadu
-
Vellore、Tamil Nadu、印度、632004
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad、Telangana、印度、500082
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Lucknow、Uttar Pradesh、印度、226007
- Novartis Investigative Site
-
-
-
-
-
Kaohsiung City、台湾、833
- Novartis Investigative Site
-
Tainan、台湾、704302
- Novartis Investigative Site
-
Taipei、台湾、10002
- Novartis Investigative Site
-
Taipei、台湾、111045
- Novartis Investigative Site
-
Taoyuan、台湾、33305
- Novartis Investigative Site
-
-
-
-
-
Belgrade、塞尔维亚、11000
- Novartis Investigative Site
-
Niš、塞尔维亚、18108
- Novartis Investigative Site
-
Novi Sad、塞尔维亚、21000
- Novartis Investigative Site
-
-
-
-
-
São Paulo、巴西、05403-000
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、巴西、40050-410
- Novartis Investigative Site
-
-
Federal District
-
Brasília、Federal District、巴西、70200-730
- Novartis Investigative Site
-
-
Rio Grande do Sul
-
Caxias do Sul、Rio Grande do Sul、巴西、95070-560
- Novartis Investigative Site
-
Porto Alegre、Rio Grande do Sul、巴西、90480-110
- Novartis Investigative Site
-
-
-
-
-
Gummersbach、德国、51643
- Novartis Investigative Site
-
Hamburg、德国、20246
- Novartis Investigative Site
-
Münster、德国、48149
- Novartis Investigative Site
-
-
Hesse
-
Frankfurt am Main、Hesse、德国、60590
- Novartis Investigative Site
-
-
-
-
BG
-
Bergamo、BG、意大利、24127
- Novartis Investigative Site
-
-
TO
-
Orbassano、TO、意大利、10043
- Novartis Investigative Site
-
-
-
-
-
Chiba、日本、2608677
- Novartis Investigative Site
-
Fukuoka、日本、8128582
- Novartis Investigative Site
-
Fukushima、日本、9601295
- Novartis Investigative Site
-
Hiroshima、日本、7348551
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo、Hokkaido、日本、0630005
- Novartis Investigative Site
-
Sapporo、Hokkaido、日本、0608543
- Novartis Investigative Site
-
-
Hyōgo
-
Nishinomiya、Hyōgo、日本、6638501
- Novartis Investigative Site
-
-
Iwate
-
Hanamaki、Iwate、日本、0250082
- Novartis Investigative Site
-
-
Miyagi
-
Sendai、Miyagi、日本、9838520
- Novartis Investigative Site
-
-
Osaka
-
Suita、Osaka、日本、5650871
- Novartis Investigative Site
-
-
Saitama
-
Higashi-Matsuyama、Saitama、日本、3550005
- Novartis Investigative Site
-
Koshigaya、Saitama、日本、3438555
- Novartis Investigative Site
-
-
Tokyo
-
Shinjuku Ku、Tokyo、日本、1600023
- Novartis Investigative Site
-
Shinjuku-ku、Tokyo、日本、1608582
- Novartis Investigative Site
-
-
-
-
-
Bordeaux、法国、33076
- Novartis Investigative Site
-
Nice、法国、06000
- Novartis Investigative Site
-
Paris、法国、75013
- Novartis Investigative Site
-
Paris、法国、75940
- Novartis Investigative Site
-
Strasbourg、法国、67081
- Novartis Investigative Site
-
Toulouse、法国、31059
- Novartis Investigative Site
-
-
-
-
-
Bydgoszcz、波兰、85-065
- Novartis Investigative Site
-
Katowice、波兰、40-689
- Novartis Investigative Site
-
Lodz、波兰、93-113
- Novartis Investigative Site
-
Lublin、波兰、20-701
- Novartis Investigative Site
-
Lublin、波兰、20-410
- Novartis Investigative Site
-
Poznan、波兰、61-731
- Novartis Investigative Site
-
Skorzewo、波兰、60-185
- Novartis Investigative Site
-
Warsaw、波兰、01-684
- Novartis Investigative Site
-
Warsaw、波兰、02-172
- Novartis Investigative Site
-
-
Lublin Voivodeship
-
Lublin、Lublin Voivodeship、波兰、20-064
- Novartis Investigative Site
-
Lublin、Lublin Voivodeship、波兰、20-080
- Novartis Investigative Site
-
-
POL
-
Krakow、POL、波兰、31-505
- Novartis Investigative Site
-
-
-
-
Victoria
-
Fitzroy、Victoria、澳大利亚、3065
- Novartis Investigative Site
-
-
-
-
-
Brasov、罗马尼亚、500283
- Novartis Investigative Site
-
Bucharest、罗马尼亚、040215
- Novartis Investigative Site
-
Sibiu、罗马尼亚、550245
- Novartis Investigative Site
-
-
-
-
Arizona
-
Phoenix、Arizona、美国、85013
- Neuromuscular Research Center
-
Scottsdale、Arizona、美国、85258
- Honor Health Research Institute
-
-
California
-
Fullerton、California、美国、92835
- Fullerton Neuro and Headache Ctr
-
Los Angeles、California、美国、90033
- University Of Southern California
-
Sacramento、California、美国、94115
- California Pacific Medical Center
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010-2975
- Medstar Washington Hospital Center
-
-
Florida
-
Boca Raton、Florida、美国、33487
- SFM Clinical Research LLC
-
Homestead、Florida、美国、33033
- Homestead Assoc In Research Inc
-
Maitland、Florida、美国、32751
- Neurology Associates PA
-
Orlando、Florida、美国、32804
- AdventHealth
-
Orlando、Florida、美国、32806
- Neurological Services of Orlando PA
-
-
Illinois
-
Chicago、Illinois、美国、60637
- University of Chicago Medical Centr
-
-
Maryland
-
Bethesda、Maryland、美国、20817-1807
- Mid Atlantic Epilepsy and Sleep Ctr
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Massachusetts General Hospital
-
-
Michigan
-
East Lansing、Michigan、美国、48824
- Michigan State University-Department of Neurology
-
-
New York
-
Buffalo、New York、美国、14209
- Dent Neurological Institute
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15213
- University of Pittsburgh Medical Center
-
-
Texas
-
Houston、Texas、美国、77030
- Houston Methodist Hospital
-
Houston、Texas、美国、77030
- UT Health Science Center
-
San Antonio、Texas、美国、78229-3900
- University of Texas Health Science Center at San Antonio
-
-
Washington
-
Seattle、Washington、美国、98195
- University of WA Division of Cardio
-
-
Wisconsin
-
Greenfield、Wisconsin、美国、53228-1321
- Center for Neurological Disorders G
-
-
-
-
-
London、英国、SW17 0QT
- Novartis Investigative Site
-
-
-
-
North Holland
-
Amsterdam、North Holland、荷兰、1105 AZ
- Novartis Investigative Site
-
-
-
-
-
Barcelona、西班牙、08035
- Novartis Investigative Site
-
Lleida、西班牙、25198
- Novartis Investigative Site
-
Madrid、西班牙、28034
- Novartis Investigative Site
-
Málaga、西班牙、29010
- Novartis Investigative Site
-
Valencia、西班牙、46026
- Novartis Investigative Site
-
-
-
-
-
Buenos Aires、阿根廷、C1012AAR
- Novartis Investigative Site
-
Caba、阿根廷、C1055AAF
- Novartis Investigative Site
-
Capital Federal、阿根廷、C1023AAB
- Novartis Investigative Site
-
San Miguel de Tucumán、阿根廷、T4000AXL
- Novartis Investigative Site
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、阿根廷、2000
- Novartis Investigative Site
-
-
-
-
-
Busan、韩国、49241
- Novartis Investigative Site
-
Seoul、韩国、03080
- Novartis Investigative Site
-
Seoul、韩国、03722
- Novartis Investigative Site
-
Seoul、韩国、05278
- Novartis Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adult patients with gMG (age 18-85 years)
- Confirmed diagnosis of Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG at screening and likely not in need of a respirator for the duration of the study, as judged by the Investigator
- Documented evidence of positive serologic testing for AChR+ antibody or MuSK+ antibody at screening, OR seronegative for both AChR and MuSK antibodies at screening
- Baseline MG-ADL score ≥ 6 with ≥ 50% of the total score due to non ocular symptoms
- Participants who have been receiving a standard-of-care treatment as specified in the protocol
- Able to safely swallow the study medication according to investigator clinical judgement based on a bedside swallowing test or another formal swallowing test in line with local practice, both at Screening and Baseline
Exclusion Criteria:
- Prior to baseline have been treated with intravenous immunoglobulins or plasma exchange (IVIg/PLEX) in the past month, with rituximab in the past 6 months, eculizumab in the past 2 months, ravulizumab or other complement inhibitors in the past 3 months, efgartigimod or other anti-FcRn therapies in the past 3 months, or had a thymectomy in the past 6 months or a planned thymectomy during the trial period
- Women of child bearing potential, defined as all women physiologically capable of becoming pregnant, from menarche until becoming post-menopausal, unless they are using highly effective methods of contraception during dosing and for 1 week after stopping of study treatment
Other protocol-defined inclusion/exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Remibrutinib arm
Core Part: Remibrutinib tablet taken orally [Extension Part: Open-label remibrutinib tablet taken orally] |
Remibrutinib (Blinded) active treatment
其他名称:
Remibrutinib (Open Label) active treatment
其他名称:
|
|
安慰剂比较:Placebo arm
Core Part: Placebo tablet taken orally [Extension Part: Open-label remibrutinib tablet taken orally] |
Placebo Remibrutinib (Open Label) active treatment
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total score
大体时间:Baseline to Month 6
|
The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24). |
Baseline to Month 6
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline to Month 6 in Quantitative Myasthenia Gravis (QMG) total score
大体时间:Baseline to Month 6
|
The Quantitative Myasthenia Gravis (QMG) Score is a 13-item direct physician assessment scoring system that quantifies disease severity, based on impairments of body functions and structures. The total QMG score ranges from 0 to 39, where higher scores indicated greater disease severity. The QMG score is composed of the following items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item) and respiratory (1 item). |
Baseline to Month 6
|
|
Proportion of participants with ≥ 5 points reduction from baseline to Month 6 of QMG total score without rescue medication and/or strongly confounding prohibited medication
大体时间:Baseline to Month 6
|
The Quantitative Myasthenia Gravis (QMG) Score is a 13-item direct physician assessment scoring system that quantifies disease severity, based on impairments of body functions and structures. The total QMG score ranges from 0 to 39, where higher scores indicated greater disease severity. The QMG score is composed of the following items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item) and respiratory (1 item). |
Baseline to Month 6
|
|
Proportion of participants with ≥ 3 points reduction from baseline to Month 6 of Myasthenia Gravis Activity of Daily Living (MG-ADL) scale total score without rescue medication and/or strongly confounding prohibited medication
大体时间:Baseline to Month 6
|
The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24). |
Baseline to Month 6
|
|
Proportion of participants achieving Minimal Symptom Expression (MSE) at Month 6, defined as MG-ADL score of 0 or 1 at Month 6 without rescue therapy and/or strongly confounding prohibited medication
大体时间:Month 6
|
The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24). |
Month 6
|
|
Change from baseline to Month 6 in Myasthenia Gravis Composite score (MGC) total score
大体时间:Baseline to Month 6
|
The MGC is a 10-item instrument that measures the symptoms and signs of MG based on physician examination and patient history. Items relate to ptosis, double vision, eye closure, talking, chewing, swallowing, breathing, neck flexion, shoulder abduction, and hip flexion. Each item is scored on an ordinal scale with 4 possible categories and weighted. The total score ranges from 0 to 50, where higher scores indicating more severe impairments. |
Baseline to Month 6
|
|
Change from baseline to Month 6 in revised Myasthenia Gravis Quality of Life Questionnaire (MG-QOL15r) survey score
大体时间:Baseline to Month 6
|
The revised MG-QoL15 is a 15-item health related quality of life questionnaire completed by participants, designed to measure quality of life in gMG. Items on the MG-QoL15 relate to physical, social, and psychological components and are scored from 0 (not at all) to 2 (very much). The cumulative scores range from 0 to 30, with higher scores representing worse quality of life and dissatisfaction with MG-related dysfunction. |
Baseline to Month 6
|
|
Incidence of adverse events
大体时间:Baseline to Month 6
|
Incidence of adverse events including changes in clinical laboratory values, vital signs, electrocardiograms and suicidality results qualifying and reported as AEs. |
Baseline to Month 6
|
|
Proportion of time during which participants showed a reduction of ≥ 2 points in MG-ADL total score, that was maintained up to Month 6
大体时间:Baseline to Month 6
|
The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24). |
Baseline to Month 6
|
|
Proportion of early MG-ADL responders during treatment (early responders with first MG-ADL improvement from baseline of ≥ 2 points occurring by week 4)
大体时间:Baseline to week 4
|
The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24). Participants with a first MG-ADL improvement from baseline of ≥ 2 points occurring by week 4 are considered early responders. |
Baseline to week 4
|
|
Change from baseline to Month 6 in EuroQol-5 Dimensions-5 Level (EQ-5D-5L)
大体时间:Baseline to Month 6
|
The EQ-5D-5L is a widely used questionnaire designed to assess health status in adults. The measure is divided into two distinct sections, the descriptive system and the EQ visual analogue scale (EQ VAS). The first section includes one item addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Participants rate each of these items from 1 of the 5 levels: no problems, slight problems, moderate problems, severe problems, or unable to/extreme. A composite health state is then defined by combining the levels for each dimension into a 5-digit number. The second section includes the EQ visual analogue scale (EQ VAS) that measures self-rated (global) health status utilizing a vertically oriented visual analogue scale where 100 represents the "best imaginable health state" and 0 represents the "worst imaginable health state." Respondents are asked to rate their current health by placing a mark along this continuum. |
Baseline to Month 6
|
|
Proportion of participants achieving a reduction from baseline of ≥ 3 points in MGC total score at Month 6
大体时间:Baseline to Month 6
|
The MGC is a 10-item instrument that measures the symptoms and signs of MG based on physician examination and patient history. Items relate to ptosis, double vision, eye closure, talking, chewing, swallowing, breathing, neck flexion, shoulder abduction, and hip flexion. Each item is scored on an ordinal scale with 4 possible categories and weighted. The total score ranges from 0 to 50, where higher scores indicating more severe impairments. |
Baseline to Month 6
|
|
Change from baseline in MG-ADL total score
大体时间:Baseline to Month 66
|
The MG-ADL is a categorical scale that assesses MG symptoms and their effects on daily activities. MG-ADL is composed of items related to patient's assessment of functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. Each item is assessed on a 4-points scale where a score 0 represents normal function and a score 3 represents loss of ability to perform that function (total score 0 to 24). |
Baseline to Month 66
|
|
Change from baseline in QMG total score
大体时间:Baseline to Month 66
|
The Quantitative Myasthenia Gravis (QMG) Score is a 13-item direct physician assessment scoring system that quantifies disease severity, based on impairments of body functions and structures. The total QMG score ranges from 0 to 39, where higher scores indicated greater disease severity. The QMG score is composed of the following items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item) and respiratory (1 item). |
Baseline to Month 66
|
|
Change from baseline in MGC total score
大体时间:Baseline to Month 66
|
The MGC is a 10-item instrument that measures the symptoms and signs of MG based on physician examination and patient history. Items relate to ptosis, double vision, eye closure, talking, chewing, swallowing, breathing, neck flexion, shoulder abduction, and hip flexion. Each item is scored on an ordinal scale with 4 possible categories and weighted. The total score ranges from 0 to 50, where higher scores indicating more severe impairments. |
Baseline to Month 66
|
|
Proportion of participants achieving a reduction from core part in oral corticosteroids (OCS) dose till the end of extension part
大体时间:Baseline to month 66
|
Participants receiving oral corticosteroids are required to be on a stable dose for at least 4 weeks prior to baseline. The dose can be reduced or discontinued during the open label extension period at investigator discretion. Oral corticosteroids use will be recorded. |
Baseline to month 66
|
|
Incidence of adverse events
大体时间:Month 7 to month 66
|
Incidence of adverse events including changes in clinical laboratory values, vital signs, electrocardiograms and suicidality results qualifying and reported as AEs. |
Month 7 to month 66
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CLOU064O12301
- 2023-510026-32 (其他标识符:EU CTIS)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.